scholarly journals The Impact of Theoretical \(\beta \)-Decay Rates on the Production of the r-Process Third Peak

Author(s):  
N. Nishimura ◽  
Zs. Podolyák ◽  
D.-L. Fang ◽  
T. Suzuki
Keyword(s):  
2020 ◽  
Vol 27 ◽  
pp. 175
Author(s):  
Stylianos Nikas ◽  
G. Martínez-Pinedo ◽  
M. R. Wu ◽  
A. Sieverding ◽  
M. P. Reiter

We present a study of nucleosynthesis for conditions of high Ye outflows from NeutronStar Mergers (NSMs). We investigate the effect of new beta-decay rates measurements and uncertaintiesin nuclear masses of the newly measured 84,85 Ga to the r-process nucleosynthesis calculations. The impactof these quantities to the production of the elements of the r-process abundance pattern for A < 100 isquantified and presented.


Author(s):  
Nguyen Kim Uyen ◽  
Kyung Yuk Chae ◽  
NgocDuy Nguyen ◽  
DuyLy Nguyen

Abstract The β--decay half-lives of extremely neutron-rich nuclei are important for understanding nucleosynthesis in the r-process. However, most of their half-lives are unknown or very uncertain, leading to the need for reliable calculations. In this study, we updated the coefficients in recent semi-empirical formulae using the newly updated mass (AME2020) and half-life (NUBASE2020) databases to improve the accuracy of the half-life prediction. In particular, we developed a new empirical model for better calculations of the β--decay half-lives of isotopes ranging in Z = 10 – 80 and N = 15-130. We examined the β--decay half-lives of the extremely neutron-rich isotopes at and around the neutron magic numbers of N = 50, 82, and 126 using either five different semi-empirical models or finite-range droplet model and quasi-particle random phase approximation (FRDM+QRPA) method. The β--decay rates derived from the estimated half-lives were used in calculations to evaluate the impact of the half-life uncertainties of the investigated nuclei on the abundance of the r-process. The results show that the half-lives mostly range in 0.001 < T1/2 < 100 s for the nuclei with a ratio of N/Z < 1.9; however, they differ significantly for those with the ratio of N/Z > 1.9. The half-life differences among the models were found to range from a few factors (for N/Z < 1.9 nuclei) to four orders of magnitude (for N/Z > 1.9). These discrepancies lead to a large uncertainty, which is up to four orders of magnitude, in the r-process abundance of isotopes. We also found that the multiple-reflection time-of-flight (MR-TOF) technique is preferable for precise mass measurements because its measuring timescale applies to the half-lives of the investigated nuclei. Finally, the results of this study are useful for studies on the β-decay of unstable isotopes and astrophysical simulations.


2017 ◽  
Vol 48 (3) ◽  
pp. 641 ◽  
Author(s):  
T. Marketin ◽  
A. Sieverding ◽  
M.-R. Wu ◽  
N. Paar ◽  
G. Martínez-Pinedo
Keyword(s):  

2020 ◽  
Vol 1668 ◽  
pp. 012029
Author(s):  
Stylianos Nikas ◽  
Gabriel Martinez Pinedo ◽  
re Sieverding

2015 ◽  
Author(s):  
Tomislav Marketin ◽  
Lutz Huther ◽  
Gabriel Martinez-Pinedo

Author(s):  
Toshio Suzuki ◽  
Takashi Yoshida ◽  
Shinya Wanajo ◽  
Toshitaka Kajino ◽  
Takaharu Otsuka

Author(s):  
Toshio Suzuki ◽  
Takashi Yoshida ◽  
Shota Shibagaki ◽  
Toshitaka Kajino ◽  
Takaharu Otsuka

Pramana ◽  
2006 ◽  
Vol 67 (2) ◽  
pp. 363-368 ◽  
Author(s):  
Kamales Kar ◽  
Soumya Chakravarti ◽  
V R Manfredi
Keyword(s):  

2020 ◽  
Vol 36 (S1) ◽  
pp. 37-37
Author(s):  
Americo Cicchetti ◽  
Rossella Di Bidino ◽  
Entela Xoxi ◽  
Irene Luccarini ◽  
Alessia Brigido

IntroductionDifferent value frameworks (VFs) have been proposed in order to translate available evidence on risk-benefit profiles of new treatments into Pricing & Reimbursement (P&R) decisions. However limited evidence is available on the impact of their implementation. It's relevant to distinguish among VFs proposed by scientific societies and providers, which usually are applicable to all treatments, and VFs elaborated by regulatory agencies and health technology assessment (HTA), which focused on specific therapeutic areas. Such heterogeneity in VFs has significant implications in terms of value dimension considered and criteria adopted to define or support a price decision.MethodsA literature research was conducted to identify already proposed or adopted VF for onco-hematology treatments. Both scientific and grey literature were investigated. Then, an ad hoc data collection was conducted for multiple myeloma; breast, prostate and urothelial cancer; and Non Small Cell Lung Cancer (NSCLC) therapies. Pharmaceutical products authorized by European Medicines Agency from January 2014 till December 2019 were identified. Primary sources of data were European Public Assessment Reports and P&R decision taken by the Italian Medicines Agency (AIFA) till September 2019.ResultsThe analysis allowed to define a taxonomy to distinguish categories of VF relevant to onco-hematological treatments. We identified the “real-world” VF that emerged given past P&R decisions taken at the Italian level. Data was collected both for clinical and economical outcomes/indicators, as well as decisions taken on innovativeness of therapies. Relevant differences emerge between the real world value framework and the one that should be applied given the normative framework of the Italian Health System.ConclusionsThe value framework that emerged from the analysis addressed issues of specific aspects of onco-hematological treatments which emerged during an ad hoc analysis conducted on treatment authorized in the last 5 years. The perspective adopted to elaborate the VF was the one of an HTA agency responsible for P&R decisions at a national level. Furthermore, comparing a real-world value framework with the one based on the general criteria defined by the national legislation, our analysis allowed identification of the most critical point of the current national P&R process in terms ofsustainability of current and future therapies as advance therapies and agnostic-tumor therapies.


Sign in / Sign up

Export Citation Format

Share Document